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modeling, event based microsimulation/patient level simulation. Health outcomes 
included survival, number-needed-to-treat, life expectancy, and quality-adjusted life 
years, time horizon and cycle length. All the studies were critically appraised using 
quality of health economic scale (QHES) and were found to be of moderate to high 
quality. Evaluated therapeutic strategies comprised chemotherapeutic combina-
tion therapies, stem cell transplantation and supportive care. ConClusions: Our 
review provides a comprehensive overview of modeling studies assessing treatment 
of DLBCL which could be used by researchers to develop novel models in DLBCL.
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ZRx McdM: A Fully Flexible Tool To SuPPoRT The locAl AdAPTATion oF 
MulTiPle-cRiTeRiA deciSion cRiTeRiA in heAlTh cARe
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objeCtives: Multiple-criteria decision analysis (MCDA) is a sub-discipline of opera-
tions research that explicitly considers multiple criteria in decision-making envi-
ronments. Formally structuring complex problems appropriately and considering 
multiple criteria explicitly leads to more informed and transparent decisions. MCDA 
methods are increasing in popularity, however existing instruments and approaches 
are rigid and do not reflect local decision making needs and preferences. ZRx MCDM 
was developed as a highly flexible tool to support the application of local multiple-
criteria decision analysis in health care. This tool was used to evaluate, as an example, 
three alternatives for the management of anemia associated with chronic kidney 
disease: Procrit, Aranesp and a Biosimliar (Epogen Zeta). Methods: There are mul-
tiple MCDA standard methods that can be applied and the ZRx MCDM tool has been 
validated against the publications of such methods. Users enter desirable data by 
selecting an appropriate number of alternatives and criteria relevant to particular 
decision-making context. Further, criteria scale and weights are defined to obtain 
results (alternatives in sequence of importance) per different MCDA calculation 
methods. Seven local decision-makers applied inter-criteria weights using visual 
analogue scale (VAS). Results: Applying the Simple Linear Adaptive Model (SLAM) 
method, the decision-making criteria as ranked in order of importance were safety, 
budget impact, cost-effectiveness and unmet medical need (equal third), patient 
preferences and strategic considerations. Global scores calculated for Aranesp were 
marginally higher than for the biosimilar (0.52 vs 0.51), whereas Procrit (0.46) scored 
lower. When Multi Attribute Value Theory (MAVT) method was further applied, total 
score differentiation was more pronounced: Aranesp, Biosimilar and Procrit (0.57, 0.50 
and 0.46). ConClusions: ZRx MCDM tool has been successfully applied in a local 
decision making context. By not relying on, or promoting, pre-defined criteria, level 
definitions and weighting/aggregation methods, the tool is fully flexible and adaptive 
to high precision local decision making needs and preferences.
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PATenT exPiRy And GeneRic PRicinG: The iMPAcT on coST- eFFecTiveneSS 
ReSulTS
Hirst A, Murphy D, Vlachaki I
WG Access Ltd, London, UK
objeCtives: Several studies have considered the change in the price of medicines 
once a medicines patent expires and exclusivity in the market place is lost. Some 
HTA bodies consider the implications of patent expiry (e.g. PHARMAC) however the 
potential impact is not considered in the NICE reference case. The aim of this study 
was to consider how including the costs of medicines after patent expiry could impact 
cost-effectiveness results. Methods: A targeted review was conducted to identify 
any studies which had considered the impact of patent expiry. The approaches were 
compared and contrasted. A review of recent treatments that have received negative 
reimbursement decisions from HTA bodies were considered to determine if generic 
pricing could have influenced the decision making process. Results: Patent expiry 
has potential to impact results, however only in a handful of selected disease areas. 
The assumptions required to implement generic pricing after patent expiry can be 
associated with considerable uncertainty, particularly around the generic price of 
medicine. Further to this, the impact that generic pricing has is dependent on both 
duration of treatment and life expectancy of modelled populations. ConClusions: 
Patent expiry offers manufactures a chance to reduce the cost associated with treat-
ment without altering health outcomes. However this is likely to offer a comparable 
discount to a majority of comparators available in the market, therefore it is likely this 
will offer the biggest benefit to the manufactures that implement it first.
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develoPMenT: A SySTeMATic liTeRATuRe Review
Manetti S, Turchetti G
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objeCtives: To systematically review the existing applications of the early 
model-based techniques to innovative biomedical devices under development. 
Furthermore, our purpose is to identify their usefulness, limitations, potential 
improvements, impact on primary stakeholders and implications. Even though the 
early Health Technology Assessment (HTA) of new medical devices is recognized 
as an integral part of the technology production, many methodological criticali-
ties still afflict this field. The high level of uncertainty, connected with the scar-
city and heterogeneity of data, needs to be faced readjusting the mainstream HTA 
methodology to support both medical technology producers and policy makers 
alongside with the R&D process. Methods: Published studies in the English lan-
guage, related to period 2000-2015, were searched using computerized databases 
(Pubmed, Scopus, ScienceDirect, Web of Science, IEE Xplore) and reference search 
of the included articles. All papers that applied the health economic modeling to 
R&D medical devices met our inclusion criteria. Given the immaturity of the field, 
we also examined conference proceedings that met the same criteria. Results: 
good separation of all relevant components. This leads to models that are easy to 
formulate, validate, understand, maintain and update.
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coST-eFFecTivneSS AnAlySiS oF ShiZoPhReniA TReATMenT wiTh 
hAloPeRidol , olAnZAPine And RiSPeRidone in boSniA And 
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Vujicic Z
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objeCtives: Schizophrenia is a persistent and costly disease, which requires a 
continuous antipsychotic treatment. In antipsychotic treatment of schizophrenia, 
the differences in terms of effectiveness, tolerance, incidence of side effects, relapse 
and costs have implications regarding the cost-effectiveness. The objective of the 
specialistic research is to investigate the cost-effectiveness of two second generation 
antipsychotics (SGA) in treatment of patients with schizophrenia in the RS health-
care system. Methods: The Markov model was developed to assess the medical 
cost-effectiveness of olanzapine and risperidone (SGA) in relation to haloperidol 
(FGA) .The cohorts of patients were adult patients diagnosed with schizophrenia . 
Transitional probabilities were taken over from a major meta-analysis conducted 
by NICE. The cost considered in this model were taken over from list of rates Health 
insurance fund (HIF). The utility (in QALY) for remission or relapse were taken over 
from a scale published by Lenart et al. The cost-effectiveness measure was the 
Incremental cost-utility ratio (ICUR) . The set threshold was 3200 EUR. Results: 
Undiscounted results of the basic cost-effectiveness analysis show ICUR for olan-
zapine= 912EUR/QALY, ICUR for risperidone = 1528 EUR/QALY. Discounted results 
show ICUR for olanzapine = 877EUR/QALY, ICUR for risperidone= 1502 EUR/QALY. 
Sensitivity analysis has shown , in case of increase in transition probability for 
relapse by 10%, olanzapine remains a cost-effective strategy, whereas risperidone 
becomes a cost-ineffective strategy. The sensitivity analysis has also shown the 
stability of the basic analysis results. ConClusions: No strategy showed itself as 
dominant, both alternative strategies having higher costs but also higher effective-
ness. The model showed that, it takes less money for a better quality in olanzapine 
than risperidone strategy, while in relation to the set threshold both strategies were 
cost-effective. Both olanzapine and risperidone have proven cost-effective strategies 
from the HIF perspective with the recommendation that olanzapine should also be 
included in the reimbursement list .
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ReviewinG The coST-eFFecTiveneSS oF cheMoTheRAPy And TARGeTed 
TheRAPy FoR MeTASTATic bReAST cAnceR
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objeCtives: To systematically review and assess the quality of model-based eco-
nomic evaluations concerning chemotherapy and targeted therapy for metastatic 
breast cancer (MBC). To analyse the impact of different modelling characteristics on 
the outcomes of these studies. Methods: The search was performed in PubMED and 
NHS EED. Inclusion criteria were: English or Dutch language, model-based economic 
evaluation, chemotherapy or targeted therapy as intervention, population diagnosed 
with MBC, published between 2000 and October 2014, reporting life-years (LY) or 
quality-adjusted life year (QALY), and reporting an incremental cost-effectiveness 
ratio (ICER). Quality of the studies was assessed through a checklist. A standardised 
extraction sheet was used to retrieve general characteristics, modelling character-
istics and results of the studies. Results: Twenty-six studies were included and 
provided fifty-two comparisons. Eighteen studies used a health state-transition model 
including the following health states: stable/progression-free disease, progression 
and death. Subgroup analyses were conducted in three studies. Studies were of poor 
quality. Administration frequency of the regimens, type of model, perspective of the 
analysis, elicitation method for utilities, total amount of QALY gained and funding 
source were not always reported. Incremental LY and incremental QALY (iQALY) var-
ied from 0.06 to 1.52 and from 0.05 to 0.60, respectively. Mean incremental cost was 
€ 18,977 (range: € -10,690 - € 84,174). Mean ICER per LY and per QALY gained were € 12,000 
(range: € 200 - € 64,000) and € 76,000 (range: € 300 - € 625,000), respectively. Seven com-
parisons were represented in two or three studies and were used to analyse the effect 
of modelling characteristics on the iQALY estimates. ConClusions: The results of 
the studies were highly variable and the quality of the studies was poor. Comparison 
of studies was hampered because of under-reporting and the limited number of stud-
ies comparing the same regimens. Consequently, no firm conclusions could be drawn 
concerning the effect of modelling characteristics on outcomes.
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deciSion-AnAlyTic ModelinG STudieS: An oveRview FoR cliniciAnS 
uSinG dlbcl AS An exAMPle
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objeCtives: Diffuse large B-cell lymphoma (DLBCL) is the most common form 
of NHL, accounting for up to 30 percent of newly diagnosed cases in the United 
States and Europe. The purpose of this study was to provide a clinician-friendly 
landscape of decision-analytic models evaluating different treatment strategies 
for DLBCL. Methods: A comprehensive search strategy was developed and a sys-
tematic literature search in Pubmed and EMBASE from 1996 to June 1, 2015 was 
queried to identify studies evaluating DLBCL treatment strategies using various 
decision-analytic models. Studies were screened using pre-defined inclusion criteria 
after which data from included trials were extracted, by two independent review-
ers and disagreements resolved by a third reviewer. We included studies that were 
published as full-text articles in English, and assessed relevant clinical endpoints, 
and summarized methodological characteristics (e.g., modeling approaches, simula-
tion techniques, health outcomes, perspectives). Results: Seven decision-analytic 
modeling studies met our inclusion criteria out of the total 289 citations. Major mod-
eling approaches adopted were: decision-tree modeling, Markov state-transition 
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model selection, health states, hypotheses, survival analysis, clinical data sources 
and the treatment of uncertainty. Results: Twelve economic evaluations in oncol-
ogy were submitted to NICE by pharmaceuticals companies (PC) between 2013 and 
2015. Seven PC submitted a MCM, two a PSM, two a semi-markov partitioned sur-
vival model, and one a semi-markov model (SMM). Differences between modeling 
techniques were classified into four items: clinical data sources (e.g. published 
aggregated data for MCM and limited IPD for PSM), structure (e.g calculation of tran-
sition probabilities for MCM), hypotheses (e.g. same transition probability of death 
between two health states for MCM), flexibility of the model (e.g. access to patient 
level data for comparators required in PSM). ConClusions: Being a more flex-
ible modeling technique, Markov models remain more frequently used compared 
to PSM. Nevertheless, PSM represent a more straightforward option when patient 
level data are available but are inappropriate when such data are not accessible 
for comparators.
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PhySiciAnS’ choice AS A coMPARAToR in clinicAl TRiAlS: chAllenGeS 
FoR PhARMAcoeconoMic ModellinG oF innovATive TReATMenTS To 
SuPPoRT heAlTh TechnoloGy ASSeSSMenTS
Mbanya Z, Madrigal AM, Wright A
PHMR Ltd, London, UK
objeCtives: To identify specific challenges for modelling to support health tech-
nology assessment (HTA) submissions using trial data where the comparator is the 
physician’s choice (PC). Methods: Most clinical trials are designed globally or inter-
nationally, with minimal consideration of individual market needs. It is increasingly 
common for investigational drugs to be compared against a mix of PC treatments 
because a standard of care (SOC) is not always clearly defined. We searched a clini-
cal trials database for registered trials where PC was the comparator. Based on the 
standard requirements for pharmacoeconomic models to support HTAs, we evaluated 
trial information to identify specific modelling challenges. Results: We found 49 reg-
istered trials using PC as the comparator and identified four specific challenges that 
require guidance from HTA bodies. (1) One or more drugs used in PC regimens may not 
be licensed for an individual market, rendering their use problematical. (2) Comparison 
made against individual PC drugs results in lower patient numbers for comparison, 
reducing analysis credibility. (3) Analysis against individual PC drugs requires breaking 
randomisation, which jeopardises trial design integrity. (4) Involvement of a PC mix 
results in the need for a full incremental analysis, which might lead to application 
rejections in circumstances where the new treatment may only have incremental 
benefits over some of the individual treatments. ConClusions: The use of PC as 
a comparator in clinical trials poses challenges that are likely to slow the process of 
access to effective, innovative treatments. HTA agency involvement early in the life 
cycle of a technology would facilitate a shared understanding of evidence require-
ments. HTA agencies should develop clear guidelines on how PC efficacy and cost 
should be used for pharmacoeconomic modelling.
PRM125
evAluATion oF The eFFecT oF cRude leAveS exTRAcT oF indiGoFeRA 
SPicATA FoRSSk.(FAbAceAe) on blood GlucoSe level oF noRMoGlyceMic, 
oRAl GlucoSe loAded And AlloxAn induced diAbeTic RodenTS
Birru EM
University of Gondar, Gondar, Ethiopia
objeCtives: to evaluate the effect of the hydro-alcoholic leaves crude extract of 
Indigofera spicata(ISP) on the blood glucose level(BGL) of normoglycemic, oral glu-
cose loaded and alloxan induced diabetic rodents. Methods: The animals were 
randomly divided into five groups (n= 6) for all the aforementioned three models. In 
all models, group-I mice provided 2%tween-80, group-II were treated with 5mg/kg 
glibenclamide and the remaining three groups(III, IV &V) were treated with 100, 200, 
and 400mg/kg dose of the extract respectively. Statistical significance of differences 
in BGLs within and between groups was analyzed by SPSS version-21 using one 
way ANOVA followed by Tukey’s post hoc multiple comparison. Results: 200mg/
kg and 400mg/kg extract treated groups of normoglycemic mice showed significant 
(p< 0.05) BGL reduction compared to the pre-exposure level. In case of OGTT model 
BGL reduction was statistically significant (p< 0.05) in only 400mg/kg exposed groups 
at the 120 minute of post-exposure compared to the initial level. However, the BGL 
reducing effect of doses of the extract at the 4th, 6th and 10thhours of post treatment 
on diabetic mice was found statistically significant compared to both the negative 
control(p< 0.001) and their respective pretreatment levels(p< 0.05). ConClusions: 
Generally the crude extract of ISP leaves have shown prominent anti-diabetic effect 
and can be therefore used as a good insight for novel anti-diabetic drug discovery 
and development with a call of further in vitro and in vivo studies.
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eFFecTiveneSS ModellinG
Hummel N1, Gsteiger S2
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objeCtives: To identify and assess disease progression models used in rheumatoid 
arthritis (RA) cost-effectiveness modelling. Methods: We examined all studies 
identified in two recent systematic literature reviews on health economic deci-
sion models evaluating RA treatments. We identified the elements in these studies 
describing disease progression and classified them by outcome measure affected 
and by model type. Results: Disease progression models concern in most cases 
the health assessment questionnaire (HAQ) score. The reported individual sampling 
models and discrete event simulation models make assumptions about improve-
ment of the HAQ when treated, depending on the patient’s type of response (e.g. 
remission, good, moderate or no response, measured by the American College of 
Rheumatology (ACR) response criteria or by the disease activity score 28 (DAS28)). 
Furthermore, they assume a long-term deterioration in the HAQ score and a rebound 
effect when the treatment stops, i.e. for example a complete loss of the initial 
Of 630 articles identified, four studies passed the inclusion criteria, and three were 
included by searching reference lists. Subsequently, we add more than 150 con-
ference papers to the screening three-step procedure. ConClusions: The use of 
modelling is promising in this context. It can be explained by the required features 
of any early cost-effectiveness evaluation seeking to inform decision making. We 
aimed at distinguishing from the previous works, addressing this methodology. It 
should be stressed the very small amount of the papers on the topic. In addition, 
we highlight the absence of ad-hoc checklist and coding to be used for the quality 
assessment of early model-based analyses and data extracted classification. This 
work also tries to advance in the definition of appropriate criteria to evaluate the 
reliability of the analysis in terms of impact on primary stakeholders.
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objeCtives: We aimed to review recently published health-economic (HE) decision 
models to assess the reporting of validation efforts. An infectious disease (seasonal 
influenza, SI) and a chronic disease (breast cancer, BC) were used as examples, 
giving a preliminary insight in the reporting of validation efforts in the overall HE 
literature. Methods: A literature search was performed in Pubmed and Embase 
to retrieve full-text HE modeling studies, published between 2008 and 2014. Type 
of evaluation, model and intervention were extracted, as well as information on 
model outcomes, journal and funding. Reporting on model validation was evalu-
ated by checking for the presence of the word validation and its conjugates, and 
by using AdViSHE, a tool which contains a structured list of relevant items for vali-
dation. Results: The literature search resulted in 53 SI and 45 BC studies. In 41 
studies (42%) the word validation or its conjugates was mentioned, but only in a 
small percentage in the context of model validation. The terminology used around 
validation was found to be ambiguous. Model validation efforts were reported in 
a minority of studies. However, some studies do show good reporting examples. 
Cross validation of study outcomes was reported most often, but the quantity and 
quality of this reporting varied. More validation efforts were reported in BC than 
in SI. ConClusions: Only a limited number of studies reported on model valida-
tion efforts, although it may be assumed that more efforts have been taken than 
were reported. In particular, the differences between SI and BC may not mean that 
less efforts were undertaken to validate SI models. Although validation is deemed 
important by many researchers, this is not reflected in the reporting habits of HE 
modeling studies. Better reporting of validation efforts would be desirable to further 
enhance decision-makers’ confidence in HE models and their outcomes.
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SenSiTiviTy AnAlySiS: how Much iMPAcT doeS iT hAve on The nice 
deciSion MAkinG PRoceSS?
Hirst A, Guy H, Murphy D
WG Access Ltd, London, UK
objeCtives: As part of economic evaluations submitted to NICE, probabilistic and 
deterministic sensitivity analysis are a requirement, with probabilistic sensitivity 
analysis being a stated preference in the NICE reference case. The aim of including 
sensitivity analysis is to identify the key areas of uncertainty, and determine the 
impact on results. The aim of this analysis was to assess what impact uncertainty 
in cost-effectiveness models has had on NICE reimbursement decisions and review 
what type of sensitivity analyses are conducted. Methods: The five most recent 
NICE appraisals for breast cancer were selected, the sensitivity analysis results 
and methods were extracted. Once extracted the results of the sensitivity analysis 
were compared and contrasted. The sensitivity analysis results were considered 
in the context of the base case results. Results: The methodology of sensitivity 
analysis conducted varied between submissions, whilst all appraisals conducted 
univariate sensitivity analysis only two reported tornado diagrams. The method 
of reporting results also varied between appraisals, of the four appraisals that had 
more than one comparator in the base case, only one appraisal conducted a multi-
way cost-effectiveness acceptability analysis. ConClusions: There are many fac-
tors that impact a NICE committees decision, therefore it is not possible to draw a 
conclusion on how the uncertainty impacted the decision making process. Of the 
appraisals assessed, there was a wide range of differences between deterministic 
and probabilistic ICERs, however it appears that this did not impact the appraisal. 
The sensitivity analysis reported across NICE submissions lacks consistency in the 
observed sample, hindering the comparison between submissions.
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how To Model SuRvivAl in coST-eFFecTiveneSS AnAlySiS? diFFeRenceS 
beTween MARkov And PARTiTioned SuRvivAl AnAlySiS ModelS
Minacori R1, Bonastre J2, Lueza B2, Marguet S2, Levy P1
1Université Paris-Dauphine, Paris, France, 2Gustave Roussy, Villejuif, France
objeCtives: The choice of a modeling approach is guided by key criteria including 
time, interaction between individuals, and the unit of analysis (cohort or individuals 
level models). Despite Markov cohort modeling (MCM) is widely used in the litera-
ture, the use of partitioned survival (PS) models tends to increase. Our objective is 
to explore the rationale for selecting either a Markov modeling approach or a PS 
approach to carry-out a cost-effectiveness analysis in oncology. Our study focuses 
on the differences between the two approaches. Methods: A literature review 
focusing on survival modeling in economic evaluation was performed in order to 
establish a list of differences between the two modeling approaches. Besides, we 
reviewed NICE’s technology appraisals (TA) in oncology medicines over the last two 
years (2013-2015) to analyze the practices and the arguments put forward to justify 
modeling choices. Data collected for each TA included: model type, rationale for 
